SEC Tracker
Get the app

Ultragenyx Pharmaceutical RARE

Ultragenyx Pharmaceutical Q2 FY25: revenue $166.5M, up 13%; diluted EPS −$1.17

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Ultragenyx Pharmaceutical reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$166.5M+13% from $147.0M in Q2 FY2410-Q income statement, on EDGAR
  2. Net income−$115.0MAgainst −$131.6M in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$1.17Against −$1.52 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$176.3M−63% from $480.7M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$108.3MAgainst −$77.0M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Ultragenyx Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Prestige Consumer Healthcare PBH public float $3.0B, Sep 30, 2025
  2. Protagonist Therapeutics PTGX public float $2.9B, Jun 30, 2025
  3. Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
  4. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  5. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025